These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 15051890)
1. Germ-line expression of an oncogenic erbB2 allele confers resistance to erbB2-induced mammary tumorigenesis. Andrechek ER; Hardy WR; Laing MA; Muller WJ Proc Natl Acad Sci U S A; 2004 Apr; 101(14):4984-9. PubMed ID: 15051890 [TBL] [Abstract][Full Text] [Related]
2. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus. Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997 [TBL] [Abstract][Full Text] [Related]
3. p27Kip1 repression of ErbB2-induced mammary tumor growth in transgenic mice involves Skp2 and Wnt/beta-catenin signaling. Hulit J; Lee RJ; Li Z; Wang C; Katiyar S; Yang J; Quong AA; Wu K; Albanese C; Russell R; Di Vizio D; Koff A; Thummala S; Zhang H; Harrell J; Sun H; Muller WJ; Inghirami G; Lisanti MP; Pestell RG Cancer Res; 2006 Sep; 66(17):8529-41. PubMed ID: 16951165 [TBL] [Abstract][Full Text] [Related]
4. Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice. Jacquemart IC; Springs AE; Chen WY Int J Oncol; 2009 Feb; 34(2):517-28. PubMed ID: 19148488 [TBL] [Abstract][Full Text] [Related]
5. Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4. Jackson-Fisher AJ; Bellinger G; Shum E; Duong JK; Perkins AS; Gassmann M; Muller W; Kent Lloyd KC; Stern DF Oncogene; 2006 Sep; 25(41):5664-72. PubMed ID: 16652155 [TBL] [Abstract][Full Text] [Related]
6. Stat3 is required for anchorage-independent growth and metastasis but not for mammary tumor development downstream of the ErbB-2 oncogene. Barbieri I; Quaglino E; Maritano D; Pannellini T; Riera L; Cavallo F; Forni G; Musiani P; Chiarle R; Poli V Mol Carcinog; 2010 Feb; 49(2):114-20. PubMed ID: 20027636 [TBL] [Abstract][Full Text] [Related]
7. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Vaillant F; Asselin-Labat ML; Shackleton M; Forrest NC; Lindeman GJ; Visvader JE Cancer Res; 2008 Oct; 68(19):7711-7. PubMed ID: 18829523 [TBL] [Abstract][Full Text] [Related]
8. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418 [TBL] [Abstract][Full Text] [Related]
9. Mouse mammary tumor virus p75 and p110 CUX1 transgenic mice develop mammary tumors of various histologic types. Cadieux C; Kedinger V; Yao L; Vadnais C; Drossos M; Paquet M; Nepveu A Cancer Res; 2009 Sep; 69(18):7188-97. PubMed ID: 19738070 [TBL] [Abstract][Full Text] [Related]
11. Developmental timing of activated erbB2 expression plays a critical role in the induction of mammary tumors. Andrechek ER; Muller WJ Cell Cycle; 2004 Sep; 3(9):1111-3. PubMed ID: 15326381 [TBL] [Abstract][Full Text] [Related]
12. Susceptibility loci affecting ERBB2/neu-induced mammary tumorigenesis in mice. Quan L; Dittmar A; Zhou Y; Hutson A; Stassen AP; Demant P Genes Chromosomes Cancer; 2012 Jul; 51(7):631-43. PubMed ID: 22419448 [TBL] [Abstract][Full Text] [Related]
13. Loss of the 14-3-3σ tumor suppressor is a critical event in ErbB2-mediated tumor progression. Ling C; Su VM; Zuo D; Muller WJ Cancer Discov; 2012 Jan; 2(1):68-81. PubMed ID: 22585169 [TBL] [Abstract][Full Text] [Related]
14. Mammary development and tumorigenesis in mice expressing a truncated human Notch4/Int3 intracellular domain (h-Int3sh). Raafat A; Bargo S; Anver MR; Callahan R Oncogene; 2004 Dec; 23(58):9401-7. PubMed ID: 15531924 [TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers. Andrechek ER; Laing MA; Girgis-Gabardo AA; Siegel PM; Cardiff RD; Muller WJ Cancer Res; 2003 Aug; 63(16):4920-6. PubMed ID: 12941816 [TBL] [Abstract][Full Text] [Related]
16. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Julien SG; Dubé N; Read M; Penney J; Paquet M; Han Y; Kennedy BP; Muller WJ; Tremblay ML Nat Genet; 2007 Mar; 39(3):338-46. PubMed ID: 17259984 [TBL] [Abstract][Full Text] [Related]
17. Mammary carcinogenesis in transgenic mice expressing a dominant-negative mutant of DNA polymerase beta in their mammary glands. Wang L; Bhattacharyya N; Rabi T; Wang L; Banerjee S Carcinogenesis; 2007 Jun; 28(6):1356-63. PubMed ID: 17166880 [TBL] [Abstract][Full Text] [Related]
19. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Sarkisian CJ; Keister BA; Stairs DB; Boxer RB; Moody SE; Chodosh LA Nat Cell Biol; 2007 May; 9(5):493-505. PubMed ID: 17450133 [TBL] [Abstract][Full Text] [Related]
20. Transcriptome characterization of human mammary cell lines expressing different levels of ERBB2 by serial analysis of gene expression. dos Santos ML; Palanch CG; Salaorni S; Da Silva WA; Nagai MA Int J Oncol; 2006 Jun; 28(6):1441-61. PubMed ID: 16685446 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]